We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG Agrees to $450M Settlement: What Does It Mean for Investors?
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical agreed to a $450 million no-fault settlement over third-party da Vinci servicing.
The settlement reduced Q3 GAAP EPS to $1.49, while adjusted EPS rose 25% year over year to $3.
Revenues grew 22% to over $3 billion, while procedures increased 15%, supporting operating momentum.
Intuitive Surgical’s (ISRG - Free Report) third-quarter 2026 earnings were impacted by a $450 million litigation settlement, reflecting the financial implications of resolving disputes involving its da Vinci ecosystem. The company reached a no-fault agreement with U.S. customers who participated in a class-action lawsuit concerning third-party remanufacturing of da Vinci instruments and third-party servicing of da Vinci systems. The settlement remains subject to court approval, with a decision not expected until 2027.
The financial impact was evident in Intuitive Surgical’s reported results. Third-quarter GAAP net income totaled $523 million, or $1.49 per share, compared with $704 million, or $1.95 per share, in the year-ago quarter. Management specifically attributed the decline in reported GAAP results to the $450 million settlement. By comparison, adjusted earnings per share reached $3, up 25% year over year. The difference between the two measures underscores how significantly the settlement affected reported profitability, even as the company delivered strong underlying operating performance. Revenues increased 22% to just over $3 billion, while procedures grew 15%.
Beyond the immediate financial charge, the agreement could be important for customer relationships. CEO David Rosa said the settlement establishes a clear framework for working with customers on third-party instrument remanufacturing and system servicing. Management believes this provides greater certainty for both parties and allows Intuitive Surgical to concentrate on advancing product safety, quality and security. Chief legal officer Gary Loeb added that the resolution strengthens customer relationships by defining how the company and its customers work together in these areas.
The settlement is expected to have a significant near-term impact on earnings, while management's focus on certainty and customer engagement underscores efforts to strengthen commercial relationships and support the long-term growth of the da Vinci ecosystem.
Peer Updates
Such litigation is not rare in the medical device industry. Several companies, including Intuitive Surgical, had previously resolved lawsuits through substantial financial settlements. Other notable settlement developments in 2026 involved Abbott Laboratories (ABT - Free Report) and Tactile Systems Technology (TCMD - Free Report) .
Abbott Laboratories reached two infant-formula settlements in 2026. On Aug. 20, the company agreed to pay approximately $670 million to resolve the Gill case and claims involving 2,000 additional infants alleging necrotizing enterocolitis linked to specialty preterm formulas. It stated that the compromise was not an admission of liability. On Sept. 14, it agreed to pay $385 million to resolve federal and state allegations tied to manufacturing compliance at its Sturgis and Casa Grande plants, without finding fault.
In the first nine months of 2026, ABT recorded about $1.07 billion as legal settlements. The GAAP EPS was hurt by these settlements as the company reported GAAP EPS of $1.67, reflecting a decline of 38.1%, while adjusted EPS was up 6.3% to $3.88 over the aforementioned period.
On July 14, Tactile Systems Technology agreed to pay $550,959 to resolve DOJ allegations that certain sales personnel submitted Medicare claims for medically unnecessary pneumatic compression devices, including Entre and Flexitouch. Prosecutors alleged that between 2019 and 2024, certain sales personnel manipulated or falsified clinical records and, in some instances, forged prescribers' signatures to obtain reimbursement.
TCMD settled the lawsuit for approximately $600,000 and stated that about $800,000, including attorneys’ fees and costs, had been paid. The court dismissed the False Claims Act claims with prejudice in August, but a separate $600,000 million relators’ fee request remains pending. However, strong sales growth and operating leverage helped the company offset the impact and its GAAP EPS gained almost 58.3% in the first nine months of 2026.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 20.7% so far this year against a 4.7% gain for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 36.82, above the industry average. But it is significantly lower than its five-year median of 66.72. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 25.9% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
ISRG Agrees to $450M Settlement: What Does It Mean for Investors?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) third-quarter 2026 earnings were impacted by a $450 million litigation settlement, reflecting the financial implications of resolving disputes involving its da Vinci ecosystem. The company reached a no-fault agreement with U.S. customers who participated in a class-action lawsuit concerning third-party remanufacturing of da Vinci instruments and third-party servicing of da Vinci systems. The settlement remains subject to court approval, with a decision not expected until 2027.
The financial impact was evident in Intuitive Surgical’s reported results. Third-quarter GAAP net income totaled $523 million, or $1.49 per share, compared with $704 million, or $1.95 per share, in the year-ago quarter. Management specifically attributed the decline in reported GAAP results to the $450 million settlement. By comparison, adjusted earnings per share reached $3, up 25% year over year. The difference between the two measures underscores how significantly the settlement affected reported profitability, even as the company delivered strong underlying operating performance. Revenues increased 22% to just over $3 billion, while procedures grew 15%.
Beyond the immediate financial charge, the agreement could be important for customer relationships. CEO David Rosa said the settlement establishes a clear framework for working with customers on third-party instrument remanufacturing and system servicing. Management believes this provides greater certainty for both parties and allows Intuitive Surgical to concentrate on advancing product safety, quality and security. Chief legal officer Gary Loeb added that the resolution strengthens customer relationships by defining how the company and its customers work together in these areas.
The settlement is expected to have a significant near-term impact on earnings, while management's focus on certainty and customer engagement underscores efforts to strengthen commercial relationships and support the long-term growth of the da Vinci ecosystem.
Peer Updates
Such litigation is not rare in the medical device industry. Several companies, including Intuitive Surgical, had previously resolved lawsuits through substantial financial settlements. Other notable settlement developments in 2026 involved Abbott Laboratories (ABT - Free Report) and Tactile Systems Technology (TCMD - Free Report) .
Abbott Laboratories reached two infant-formula settlements in 2026. On Aug. 20, the company agreed to pay approximately $670 million to resolve the Gill case and claims involving 2,000 additional infants alleging necrotizing enterocolitis linked to specialty preterm formulas. It stated that the compromise was not an admission of liability. On Sept. 14, it agreed to pay $385 million to resolve federal and state allegations tied to manufacturing compliance at its Sturgis and Casa Grande plants, without finding fault.
In the first nine months of 2026, ABT recorded about $1.07 billion as legal settlements. The GAAP EPS was hurt by these settlements as the company reported GAAP EPS of $1.67, reflecting a decline of 38.1%, while adjusted EPS was up 6.3% to $3.88 over the aforementioned period.
On July 14, Tactile Systems Technology agreed to pay $550,959 to resolve DOJ allegations that certain sales personnel submitted Medicare claims for medically unnecessary pneumatic compression devices, including Entre and Flexitouch. Prosecutors alleged that between 2019 and 2024, certain sales personnel manipulated or falsified clinical records and, in some instances, forged prescribers' signatures to obtain reimbursement.
TCMD settled the lawsuit for approximately $600,000 and stated that about $800,000, including attorneys’ fees and costs, had been paid. The court dismissed the False Claims Act claims with prejudice in August, but a separate $600,000 million relators’ fee request remains pending. However, strong sales growth and operating leverage helped the company offset the impact and its GAAP EPS gained almost 58.3% in the first nine months of 2026.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 20.7% so far this year against a 4.7% gain for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 36.82, above the industry average. But it is significantly lower than its five-year median of 66.72. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 25.9% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.